Antibodies elicited by the widely deployed rVSV-EBOV Ebola virus vaccine mirror those of disease survivors, animal models and other vaccine platforms. Notably, neutralizing antibodies are consistently elicited from a recurring pair of germline genes.
This is a preview of subscription content
Subscription info for Chinese customers
We have a dedicated website for our Chinese customers. Please go to naturechina.com to subscribe to this journal.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Ehrhardt, S. A. Nat. Med. s41591-019-0602-4 (2019).
Corti, D. et al. Science 351, 1339–1342 (2016).
Misasi, J. et al. Science 351, 1343–1346 (2016).
Davis, C. W. et al. Cell 177, 1566–1582 (2019).
Saphire, E. O. et al. Cell 174, 938–952 (2018).
Bornholdt, Z. A. et al. Science 351, 1078–1083 (2016).
Rijal, P. et al. Cell Rep. 27, 172–186.e7 (2019).
Henao-Restrepo, A. M. et al. Lancet 389, 505–518 (2017).
The author declares no competing interests.
About this article
Cite this article
Saphire, E.O. A glimpse into immune responses evolving against Ebola virus. Nat Med 25, 1470–1471 (2019). https://doi.org/10.1038/s41591-019-0607-z